morn announc plan acquir loxo premium
impli multipl revenu vitrakvi bayer partnership
believ deal price fair unlik contest like close
guid therefor move market perform
news outperform cover steve scala loxo announc
agreement lilli acquir loxo all-cash tender offer
aggreg basi valu loxo net cash repres
premium approxim close share price januari
lilli call lilli manag note major valuat associ
loxo ret inhibitor pivot develop smaller contribut
vitrakvi fda approv trk inhibitor partner bayer minor contribut
non-coval btk inhibitor began clinic develop last month lilli
also note intend continu copromot partnership bayer vitrakvi
take believ deal repres fair offer given impli multipl
sale model peak sale vitrakvi revenu bayer
partnership approxim peak valuat addit
high profil lead us believ interest acquir alreadi made
known make emerg higher bidder unlik
addit view probabl materi advers event occur loxo
on-going clinic trial low main driver lilli acquisit offer
use treat patient major toxic issu competitor
ret inhibitor also well toler demonstr gener safeti
potent ret inhibit furthermor expect file fda approv
year-end suggest data readout pivot phase ii trial
deal close loxo trk inhibitor vitrakvi second-most import program
lilli approv fda novemb make odd meaning toxic
signal slim none expect loxo second trk inhibitor phase i/ii data
anticip differ final start phase open-label
trial intern readout dose escal phase possibl doubt lilli
willing complet transact would neg influenc concern
data point therefor expect announc deal proceed closur end
guid downgrad loxo share market perform
pleas see page report import disclosur
factor support invest opinion loxo share includ best class efficaci
trk inhibitor larotrectinib strong earli proof-of-concept data
compani focu target therapeut cancer credibl
experienc manag team expect complet offer acquir loxo
phase i/ii data
registr data
larotrectinib revenu
revenu
durabl larotrectinib and/or
drive meaning increas
competitor bid reveal
clinic regulatori setback
eli lilli deal fail close
loxo oncolog early-stag compani focus develop target
therapeut patient genet defin cancer loxo found
goal combin novel biolog insight lead chemistri clinic develop
expertis rapidli effici develop small molecul drug candid target
cancer subpopul lead compound larotrectinib inhibitor tropomyosin
receptor kinas trk famili approv novemb tumor-agnost
label loxo leverag collabor array biopharma creat pipelin
addit target oncolog drug candid compound next gen
trk inhibitor target ret gener proof-of-concept efficaci earli
loxo oncolog develop target therapeut patient genet defin
cancer lead compound larotrectinib inhibitor tropomyosin
receptor kinas trk famili implic drive
advanc solid tumor includ subset soft tissu sarcoma gist salivari lung
colorect breast numer other larotrectinib produc robust orr
durabl respons trk-fusion patient across three phase ii studi
regardless tumor type specif genet transloc patient age base upon
data loxo receiv fda approv novemb partner
bayer larotrectinib commerci second gener trk inhibitor lox-
also produc proof-of-concept data larotrectinib-resist patient
extend durat across trk fusion patient treat loxo
franchis therapi current low rate trk fusion diagnosi constrain
initi adopt loxo believ annual incid advanc cancer patient
trk fusion light larotrectinib earli impress
durabl data might equat world-wide sale opportun loxo
work chemistri partner array biopharma arri outperform-r creat
pipelin addit five candid includ inhibitor target ret fgfr
kinas phase clinic trial data ret inhibitor present
show efficaci near support fda approv nda submiss
expect late model peak world-wide sale loxo also
acquir preclin revers btk inhibitor redx juli
began phase develop januari announc offer
acquir loxo expect deal close
present updat phase data gener trk inhibitor
registr data libretto trial
partner illumina releas fda approv timelin trusight tumor assay
cowen compani
cowen compani
cowen compani
partnership commerci larotrectinib profit larotrectinib ex-u partnership mileston bayer partnership salesoth collabor grant rate incom incom base comp non-gaap net incom dilut share partnership commerci larotrectinib profit larotrectinib ex-u partnership mileston bayer partnership collabor grant rate incom incom base comp non-gaap net incom cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
loxo oncolog unprofit approv product like need rais
addit capit public market prior turn profit loxo lead candid
larotrectinib face number clinic regulatori commerci hurdl prior becom
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock loxo oncolog odon secur
cowen compani llc act underwrit announc initi public offer elanco anim health incorpor subsidiari co
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
